A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Safety Study of Inhaled N-IP-00001 to Determine Tolerability and Safety in Healthy Volunteers.
Latest Information Update: 05 Nov 2024
Price :
$35 *
At a glance
- Drugs N IP 00001 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- 05 Nov 2024 New trial record